J drug shows guarantee in high-risk prostate cancer

<p>(Reuters) – Adding Johnson Johnson’s modernized <span>prostate cancer</span> drug, <span>Zytiga</span>, to <span>hormone therapy</span> before medicine has been shown for a initial time to exterminate tumors in some organisation with high-risk forms of a disease.</p>
<p> The mid-stage hearing found that 6 months of diagnosis with a multiple therapy totally or scarcely separated a <span>cancer</span> in a third of patients, all of whom had localized, <span>aggressive cancer</span>.</p>
<p> “These formula are really impressive, generally given these high-risk patients,” Dr Mary-Ellen Taplin, associate highbrow of Medicine during Harvard Medical School and a study’s lead author, pronounced during a news conference.</p>
<p> Zytiga is already authorized to provide modernized prostate cancer in patients who formerly perceived chemotherapy. JJ expect...